inclusion criteria: - willing and able to provide informed consent prior to any study procedures - severe acute respiratory syndrome coronavirus (sars-cov)-2 infection confirmed by polymerase chain reaction (pcr) test ≤ 2 days before randomization - currently hospitalized and requiring medical care for covid-19 - peripheral capillary oxygen saturation (spo2) < 94% on room air at screening exclusion criteria - participation in any other clinical trial of an experimental treatment for covid-19 - concurrent treatment with other agents outside the standard of care than 24 hours prior to study intervention dosing - requiring mechanical ventilation at screening - alanine aminotransferase (alt) or aspartate aminotransferase (ast) above 5 times upper limit of normal (uln) - creatinine clearance < 50 ml/min using the cockcroft-gault formula

inclusion criteria: - willing and able to provide informed consent prior to any study procedures - severe acute respiratory syndrome coronavirus (sars-cov)-2 infection confirmed by polymerase chain reaction (pcr) test ≤ 2 days before randomization - currently hospitalized and requiring medical care for covid-19 - peripheral capillary oxygen saturation (spo2) < 94% on room air at screening exclusion criteria - participation in any other clinical trial of an experimental treatment for covid-19 - concurrent treatment with other agents outside the standard of care than 24 hours prior to study intervention dosing - requiring mechanical ventilation at screening - alanine aminotransferase (alt) or aspartate aminotransferase (ast) above 5 times upper limit of normal (uln) - creatinine clearance < 50 ml/min using the cockcroft-gault formula